EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Clara Mazagatos iD, Jacobo Mendioroz, Mercedes Belén Rumayor, Virtudes Gallardo García, Virginia Álvarez Río, Ana Delia Cebollada Gracia, Noa Batalla Rebollo, María Isabel Barranco Boada, Olaia Pérez-Martínez, Ana Sofía Lameiras Azevedo iD, Nieves López González-Coviella, Daniel Castrillejo und 7 weitere

Influenza and Other Respiratory Viruses · 2024-05 · 18 (5)

DOI: 10.1111/irv.13294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 08.05.2024. Verfasst von Clara Mazagatos und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Antiviral Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ECDC, European Centre for Disease Prevention and Control.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.

Methods

Estimated RSV hospitalisations in < 1‐year‐olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.

Results

We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationAntiviral AgentsHumansSpainInfantIncidenceFemaleMaleRespiratory Syncytial Virus, HumanSentinel SurveillanceInfant, NewbornAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

SARIburdenimpactrespiratory infectionsrespiratory syncitial virussurveillance

Substanzen

Antiviral AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • CIBER Epidemiology and Public Health, Madrid, Spain.
  • Sub-direcció General de Vigilància i Resposta a Emergències de Salut Pública, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain.
  • Área de Enfermedades Transmisibles, Subdirección General de Vigilancia en Salud Pública, Madrid, Spain.
  • Servicio de Vigilancia y Salud Laboral, Dirección General de Salud Pública y Ordenación Farmacéutica, Consejería de Salud y Consumo, Andalucía, Spain.
  • Servicio de Epidemiología, Consejería de Sanidad, Dirección General de Salud Pública, Junta de Castilla y León, Valladolid, Spain.

ORCID-Profile: Clara Mazagatos, Ana Sofía Lameiras Azevedo, Amparo Larrauri

Förderung

  • ECDC
  • European Centre for Disease Prevention and Control

Zitieren

APA

Mazagatos, C., Mendioroz, J., Rumayor, M. B., Gallardo García, V., Álvarez Río, V., Cebollada Gracia, A. D., Batalla Rebollo, N., Barranco Boada, M. I., Pérez-Martínez, O., Lameiras Azevedo, A. S., López González-Coviella, N., Castrillejo, D., Fernández Ibáñez, A., Giménez Duran, J., Ramírez Córcoles, C., Ramos Marín, V., Larrauri, A., Monge, S., & SARI Sentinel Surveillance RSV Study Group (2024). Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain. Influenza and Other Respiratory Viruses, 18(5). https://doi.org/10.1111/irv.13294

Vancouver

Mazagatos C, Mendioroz J, Rumayor MB, Gallardo García V, Álvarez Río V, Cebollada Gracia AD, et al. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain. Influenza and Other Respiratory Viruses. 2024;18(5). doi:10.1111/irv.13294

BibTeX
@article{Mazagatos2024,
  author = {Mazagatos, Clara and Mendioroz, Jacobo and Rumayor, Mercedes Belén and Gallardo García, Virtudes and Álvarez Río, Virginia and Cebollada Gracia, Ana Delia and Batalla Rebollo, Noa and Barranco Boada, María Isabel and Pérez-Martínez, Olaia and Lameiras Azevedo, Ana Sofía and López González-Coviella, Nieves and Castrillejo, Daniel and Fernández Ibáñez, Ana and Giménez Duran, Jaume and Ramírez Córcoles, Cristina and Ramos Marín, Violeta and Larrauri, Amparo and Monge, Susana and SARI Sentinel Surveillance RSV Study Group, SARI Sentinel Surveillance RSV Study Group},
  title = {Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  volume = {18},
  number = {5},
  doi = {10.1111/irv.13294}
}
Kostenlos starten →